Carregant...
CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV
INTRODUCTION: The chemokine receptor CCR5 has garnered significant attention in recent years as a target to treat HIV infection largely due to the approval and success of the drug Maraviroc. The side effects and inefficiencies with other first generation agents led to failed clinical trials, prompti...
Guardat en:
| Publicat a: | Expert Opin Investig Drugs |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5776690/ https://ncbi.nlm.nih.gov/pubmed/27791451 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2016.1254615 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|